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Background: With advances in modern radiotherapy (RT), many patients with head and neck (HN) cancer can be
effectively cured. However, xerostomia is a common complication in patients after RT for HN cancer. The purpose
of this study was to use the Lyman–Kutcher–Burman (LKB) model to derive parameters for the normal tissue
complication probability (NTCP) for xerostomia based on scintigraphy assessments and quality of life (QoL)
questionnaires. We performed validation tests of the Quantitative Analysis of Normal Tissue Effects in the Clinic
(QUANTEC) guidelines against prospectively collected QoL and salivary scintigraphic data.
Methods: Thirty-one patients with HN cancer were enrolled. Salivary excretion factors (SEFs) measured by
scintigraphy and QoL data from self-reported questionnaires were used for NTCP modeling to describe the
incidence of grade 3+ xerostomia. The NTCP parameters estimated from the QoL and SEF datasets were compared.
Model performance was assessed using Pearson’s chi-squared test, Nagelkerke’s R2, the area under the receiver
operating characteristic curve, and the Hosmer–Lemeshow test. The negative predictive value (NPV) was checked
for the rate of correctly predicting the lack of incidence. Pearson’s chi-squared test was used to test the goodness
of fit and association.
Results: Using the LKB NTCP model and assuming n=1, the dose for uniform irradiation of the whole or partial
volume of the parotid gland that results in 50% probability of a complication (TD50) and the slope of the dose–
response curve (m) were determined from the QoL and SEF datasets, respectively. The NTCP-fitted parameters for
local disease were TD50=43.6 Gy and m=0.18 with the SEF data, and TD50=44.1 Gy and m=0.11 with the QoL data.
The rate of grade 3+ xerostomia for treatment plans meeting the QUANTEC guidelines was specifically predicted,
with a NPV of 100%, using either the QoL or SEF dataset.
Conclusions: Our study shows the agreement between the NTCP parameter modeling based on SEF and QoL
data, which gave a NPV of 100% with each dataset, and the QUANTEC guidelines, thus validating the cut-off values
of 20 and 25 Gy. Based on these results, we believe that the QUANTEC 25/20-Gy spared-gland mean-dose
guidelines are clinically useful for avoiding xerostomia in the HN cohort.
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Head and neck (HN) cancer is a leading cause of cancer
mortality in Taiwan, and radiotherapy (RT) plays an im-
portant role in its treatment. Xerostomia is a common
complication after RT for HN [1-5]. Severe xerostomia is
defined as long-term salivary dysfunction compared with
the pre-RT function, based on the Late Effects of Nor-
mal Tissues–Subjective, Objective, Management, Ana-
lytic (LENT–SOMA) criteria [6-8].
Whole-mouth salivary function has been shown to be
related to quality of life (QoL) [9,10] and has been used
to compare different treatment strategies in clinical
oncology trials. Kakoei et al. [11] have shown that the
decrease in saliva and xerostomia resulting from RT
can negatively affect QoL for patients who undergo
RT. Several prospective studies conducted over the
past decade have reported the RT dose constraints to
allow preservation of parotid gland function based on
salivary flow measurements or salivary gland scintig-
raphy [10,12-14].
In the present prospective study, we longitudinally ob-
served parotid gland function using salivary scintigraphy
to measure the salivary excretion factor (SEF) in pa-
tients receiving intensity-modulated radiotherapy (IMRT).
Moreover, a self-reported QoL questionnaire (QLQ-C30)
and a xerostomia-specific questionnaire (QLQ-H&N35)
were completed by patients before RT and periodically
after therapy to assess the interrelationships with sali-
vary function. The normal tissue complication proba-
bility (NTCP) model proposed by Lyman has been
used to determine the dose for uniform irradiation of
the whole or partial volume of the parotid gland that
results in 50% probability of a complication (TD50) in
patients with local disease [15,16]. NTCP-fitted para-




Between August 2007 and June 2008, 65 HN cancer
patients who had undergone primary or postoperative
RT for various malignancies were initially included in
the study. Patients who suffered from Sјögren’s syn-
drome or any other medical cause of xerostomia were
excluded. The use of any medication known to affect sa-
livary gland function was prohibited. After eliminating
patients because of missed appointments, refusal, and
organizational problems, it was possible to objectively
evaluate parotid gland function using scintigraphy and
QoL questionnaires after RT initiation in 31 patients.
The present prospective study enrolled these 31 HN
cancer patients who received primary (n=15) or post-
operative RT (n=16) with IMRT at Chiayi Chang Gung
Memorial Hospital of the Chang Gung MedicalFoundation. Nineteen patients received concurrent
chemotherapy: 18 received five to seven courses of
weekly cisplatin (40 mg/m2 CDDP), and one received two
courses of a PF regimen (80 mg/m2 CDDP on day 1 + 800
mg/m2 5-FU on days 1–5, every 21 days). Five of these
patients received additional adjuvant chemotherapy
with a PF regimen for two to three courses (n=4) or a
TEF regimen (60 mg/m2 taxol on day 1 + 20 mg/m2
CDDP on day 1 + 800 mg/m2 5-FU on days 1–2) for one
course (n=1).
Patients with successful salivary flow scintigraphy ima-
ging and full completion of QoL questionnaires before
and during 1 year after treatment were included. No
data were missing for these 31 patients. This study was
approved by the institutional review board of the hos-
pital (IRB-95-1430B).
RT techniques
Patients were immobilized from head to shoulders using
a commercially available thermoplastic mask and/or an
individually customized bite block. Computed tomog-
raphy (CT) images (2.5-mm slice thickness) acquired
from the top of the vertex to the level of the carina, con-
taining 512 × 512 pixels in each slice, were examined.
Both parotid glands were delineated by a radiation on-
cologist. We used the Pinnacle treatment planning sys-
tem to perform inverse planning and dose optimization.
For each patient, IMRT plans with five or seven coplanar
portals were created. Dose distributions were calculated,
and separate dose-volume histograms (DVHs) were ge-
nerated for each parotid gland, enabling each gland to
be analyzed separately. IMRT treatment mode was used
in a sequential method [3].
IMRT was delivered by a computer-controlled and
auto-sequencing segmented or dynamic multileaf colli-
mator of a linear accelerator (Varian Clinac 21 EX or
Elekta Precise), with the aim of sparing the parotid
glands (predominantly contralateral side) while treating
the primary targets and lymph nodes at risk. The pre-
scribed doses were 67.4 to 70.8 Gy (mean dose, 69.8 Gy)
to the macroscopic tumor planning target volume
(PTV1), 54.8 to 70.8 Gy (mean dose, 62.0 Gy) to the
resected tumor bed planning target volume (PTV2), and
46.8 Gy to the subclinical disease planning target volume
(PTV3), delivered at 1.8 to 2 Gy per fraction.
Based on the Radiation Therapy Oncology Group
studies 0615, and 0225 [17], the planning objectives for
PTVs were a minimum dose to >95% of the target, with
no more than 5% of any PTV1 receiving ≥110% of the
prescribed dose. The structural constraints used were a
parotid gland mean dose of ≤26 Gy or V30Gy ≤50%; for
the oral cavity excluding the PTV, the mean dose must
be ≤40 Gy. The mean DVH values for the parotid gland
were calculated for each patient. All data are based on
Table 1 Patients and tumor characteristics
































Parotid gland mean dose
Ipsilateral, mean (range) 51.7 (26.9-74.8) Gy








Grade 3+ xerostomia 10 (16.1)
No grade 3+ xerostomia 52 (83.9)
QoL measurement*
Grade 3+ xerostomia 6 (19.4)
No grade 3+ xerostomia 25 (80.6)
*SEF recovery and QoL measurement was at 1-year after RT. Grade 3+: ≧grade 3.
Abbreviation: RT radiotherapy, SEF salivary excretion factorm, QoL quality of life.
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resolution of 0.01 Gy. The dose calculation resolution
was 2.5 mm for all IMRT plans.
Salivary gland scintigraphy
All patients received salivary scintigraphy. Stimulated
whole-mouth saliva was collected before RT and at
various time intervals; for this analysis, the 1-year fol-
low-up time point was used. Scintigraphy was per-
formed after 4 h of fasting. After the patient received
an intravenous injection of 10 mCi of 99mTc pertech-
netate, sequential images of the left and right anterior
views of the head and neck were acquired at 1 min/
frame for 30 min. Major salivary gland function was
represented by saliva excretion after sialogogue stimu-
lation with acidic material. The salivary excretion fac-
tor (SEF) was determined as the maximal excretion
activity per gland as a function of the maximal up-
take [13].
Parotid gland function measured as the SEF by salivary
scintigraphy was evaluated before RT and at 1 and 2
years after RT. All patients received scintigraphy 1 year
after RT, whereas only 25 patients (25/31, 81%) were
examined 2 years after RT. Scintigraphy was not per-
formed for six patients because of tumor recurrence
(n=2) or patient refusal (n=4). The excretion response
was analyzed per patient and subsequently per individual
gland. The primary end point was set as the salivary flow
≤45% of the pre-RT value [18], which is equivalent to
grade 3+ xerostomia based on the dry mouth subscales
of LENT-SOMA criteria (subjective: xerostomia, ana-
lytic: salivary flow), where grade 1 is 76–95% of pre-RT
salivary flow; grade 2, 51–75%; grade 3, 26–50%; and
grade 4, 0–25% [7,8].
NTCP data fitting
All DVH data for each patient were transferred to
MATLAB (version R2009b), and the analysis, including
95% confidence intervals, was performed with SPSS for
Windows (version 17.0; SPSS, Chicago, IL) using the
same dataset and selected variables. The data were fit
to the Lyman-Kutcher-Burman (LKB) NTCP model
[15,16]. The model quantitatively assesses the effects of
both the radiation dose and the volume of the gland
irradiated on the probability of radiation-induced chan-
ges in parotid gland function. Three parameters are re-
presented in the sigmoidal dose–response curve: n, m,
and TD50. The parameter n accounts for the volume ef-
fect of an organ: n was set to 1 in this study. The para-
meter m describes the slope of the dose–response curve,
where decreasing m indicates increasing steepness of the
slope. The TD50 is the dose for uniform irradiation of
the whole or partial volume resulting in 50% probability
of a complication. The NTCP is calculated from the
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t ¼ EUD TD50
m⋅TD50
ð2Þ
The EUD is defined as the uniform dose that would
lead to the same level of tumor-cell killing as a non-
uniform dose. Recently, the EUD concept has also been
applied in normal tissues to evaluate the harm of a non-
uniform dose distribution with the same result as a spe-










where N is the number of voxels of the organ; Di is the
dose of the i-th voxel; vi is the volume of the i-th voxel;
and n is a parameter reflecting the biological properties
of the organ related to its serial (0 < n << 1) or parallel
structure (n of approximately 1). When n=1, the EUD
is equal to the mean dose, as described previously
[15,20,21]. The simplified LKB model represents the in-
tegral used in the Lyman formula as an exponential of a
second-degree polynomial of dose.
QoL evaluation
The EORTC questionnaire was chosen for this research
because it is one of the most widely implemented ques-
tionnaires, with more than 10 years of research invested
to develop an integrated, modular approach. Moreover,
it has been used in international clinical trials, and
the Taiwan Chinese version is easily completed by our
patients. The traditional Chinese version of the EORTC
QLQ-H&N35 questionnaire, obtained from the Quality
of Life Unit, EORTC Data Center in Brussels, Belgium
[22,23], was used for a prospective QoL survey. The pri-
mary endpoint (grade 3+ xerostomia) was defined as
moderate to severe xerostomia 1 year after the comple-




Parotid mean dose −0.807 −0.759
Age (≥ 50 vs. <50) 0.146 0.141
Tumor site (oral cavity vs. non-oral cavity) −0.116 −0.101
Surgery (yes vs. no) −0.052 −0.092
Chemotherapy (yes vs. no) 0.017 0.166
*Factors associated with recovery of parotid gland function at 1 year after radiotherensure that xerostomia was induced primarily by the
radiation treatment, patients with moderate to severe
xerostomia at baseline were excluded from the analysis.
All scales pertaining to the EORTC QLQ-H&N35 ranged
from 0 to 100. A high score for a functional or global QoL
scale represents a relatively high/healthy level of function-
ing or global QoL, whereas a high score for a symptom
scale represents the presence of a symptom or problems
[24-27]. All patients completed all questionnaires at three
time points (before RT and at 3 and 12 months after RT),
but only 17 patients (54.8%) completed the questionnaires
at 2 years after RT. Thus, only the 1-year data were ana-
lyzed in the present study.
QUANTEC guidelines
The Quantitative Analysis of Normal Tissue Effects in the
Clinic (QUANTEC) guidelines are a recent concerted effort
by the RT community to review and summarize normal
tissue toxicity, which may suggest dose-volume treatment
planning guidelines and likely reduce the rates of side
effects. QUANTEC guidelines to limit the probability of
severe xerostomia recommend that at least one parotid
gland should receive a mean dose of ≤20 Gy or both pa-
rotid glands should receive a mean dose of ≤25 Gy
[28,29]. We performed a validation test of these guidelines
using prospectively collected QoL and salivary scinti-
graphic datasets.
Statistical analyses
Spearman’s correlation was used to check the correlation
between parotid gland excretion recovery at 1 year af-
ter RT and the mean parotid gland dose. To identify
the patient- or treatment-related factors associated with
parotid function recovery, we statistically analyzed age,
tumor site, parotid mean dose, surgery, and chemothe-
rapy using Spearman’s correlation and univariate and
multivariate analysis. The mean scores and standard de-
viations of the QoL scales were calculated according
to the EORTC QLQ scoring manual. To validate the
QUANTEC constraints at the cut-off points of 20 Gy
and 25 Gy, the negative predictive value (NPV) was
checked for the rate of correctly predicting the lack of
xerostomia. Positive predictive value (PPV) is the pro-












Figure 3 Comparison of the curves for the normal tissue
complication probability (NTCP) at 1 year after radiotherapy
based on the salivary excretion factor and quality of life datasets.
Figure 1 The observed salivary excretion factor (SEF) data
and the fitted dose–response curve for the normal tissue
complication probability of the incidence of grade 3+ xerostomia
(salivary flow ≤45% relative to pre-RT) at 1 year after
radiotherapy as a function of the mean dose to the spared
parotid gland. Dashed lines show 95% confidence intervals for the
model fit to the SEF data (solid line). The squares represented the
group patient mean doses in bins 4-Gy width. (All individual dose
data points were used in the NTCP fitting).
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listed in equations 4 and 5. Pearson’s chi-squared test
was used to test goodness of fit and associations for both
the SEF and QoL data. Overall performance was mea-
sured by Nagelkerke’s R2, which quantifies the amount
of variation explained by the model. Model performance
was also evaluated using measures for discriminative
ability, including the area under the receiver operatingFigure 2 The observed quality of life (QoL) data and the fitted
dose–response curve for the normal tissue complication
probability of the incidence of grade 3+ xerostomia. (The
endpoint was defined as moderate to severe xerostomia 1 year after
the completion of RT on the QLQ-HN35 questionnaires). Dashed
lines show 95% confidence intervals for the model fit to the QoL
data (solid line). The squares represented the average probability for
groups of patients in bins 4-Gy width. (All individual data points
were used in the NTCP fitting).characteristic curve (AUC). The Hosmer–Lemeshow test
was used for calibration processing to test the goodness
of fit for the hypothesis that the model and observed
outcomes were in agreement [2]. Values of p < 0.05 indi-
cated statistical significance. All analyses were performed
using SPSS 17.0.
PPV ¼ sensitivity prevalence
sensitivity  prevalence þ 1 specificityð Þ  1 prevalenceð Þ
ð4Þ
NPV ¼ specificity  1 prevalenceð Þ
1 sensitivityð Þ  prevalenceþ specificity 1 prevalenceð Þ
ð5Þ
Results
The demographic and tumor characteristics of the study
population are listed in Table 1. After a median follow-
up of 46.8 months (range, 34.9–62.3 months), 30 (97%)
of the 31 patients were still alive. One patient had died
of other disease (lung cancer). Among the 30 surviving
patients, 25 were still disease free, and five patients had
distant metastasis. All scintigraphic examinations and QoLTable 3 Predictive values for the QUANTEC guidelines




PPV (%) NPV (%) PPV (%) NPV (%)
20-QUANTEC 19.2 100 23.1 100
25-QUANTEC 20.0 100 24.0 100
43.6-SEF-NTCP 50.0 92.0 45.5 95.0
44.1-QoL-NTCP 50.0 88.9 55.6 95.5
Abbreviation: SEF salivary excretion factor, QoL quality of life, PPV positive
predictive value, NPV negative predictive value, NTCP normal tissue
complication probability, QUANTEC Quantitative Analyses of Normal Tissue
Effects in the Clinic.
Table 4 Model performance and internal validation for
the normal tissue complication probability model
Performance measure SEF QoL
Nagelkerke R2 0.12 0.11
AUC 0.75 0.75
Hosmer–Lemeshow test χ2 = 10.2 (p = 0.24) χ2 = 7.76 (p = 0.46)
Abbreviation: AUC area under the receiver operating characteristic curve;
SEF salivary excretion factor, QoL quality of life.
Figure 5 Summary of the 25/20-Gy guidelines for radiotherapy
in head and neck cancer patients applied to the quality of life
(QoL) data at 1 year after radiotherapy. The rate of xerostomia
for plans meeting the QUANTEC guideline was zero, resulting in a
NPV of 100% under the cut-off point. black circle: Grade 3+
xerostomia; white circle: No grade 3+ xerostomia.
Figure 4 Summary of the 25/20-Gy guidelines for radiotherapy
in head and neck cancer patients applied to the salivary
excretion factor (SEF) data at 1 year after radiotherapy. The rate
of xerostomia for plans meeting the QUANTEC guideline was zero,
resulting in a NPV of 100% under the cut-off point. black circle:
Grade 3+ xerostomia; white circle: No grade 3+ xerostomia.
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Dosimetry analysis showed that the ipsilateral parotid
gland received a dose ranging from 26.9 to 74.8 Gy
(mean, 51.7 Gy), and the contralateral lobe received 7.6 to
57.6 Gy (mean, 36.7 Gy).
The SEF values before RT showed a normal distribu-
tion (mean, 48.1% ± 18.2%). Parotid gland output varied
considerably, from 19.2 to 72.8%. The relationships between
parotid gland excretion recovery at 1 year and patient age,
tumor site, parotid gland mean dose, surgery, and chemo-
therapy were analyzed (Table 2). Only parotid gland mean
dose was significantly correlated with recovery of parotid
gland function at 1 year (r=−0.807; r2=0.651; p < 0.001).
Figure 1 shows the observed SEF data and the fitted
dose–response curves (LKB NTCP model) for the inci-
dence of xerostomia at 1 year after completion of RT.
The local fitted parameters are TD50=43.6 Gy (CI: 41.3-
45.9 Gy) and m=0.18 (CI: 0.17-0.19). Dashed lines show
the 95% confidence interval for the model fit to the SEF
dataset (solid line). The incidences of grade 3+ xerosto-
mia at 1 year were ~1% and ~2% for the recommended
cut-off points of 20 and 25 Gy, respectively. Figure 2
presents the observed QoL data and fitted dose–response
curves for the incidence of xerostomia at 1 year after RT.
The fitted parameters are TD50=44.1 Gy (CI: 41.7-46.5
Gy) and m=0.11 (CI: 0.10-0.12). The curves for the two
datasets are compared in Figure 3.
The positive and negative predictive values are listed
on Table 3, the cut-off points were set for the QUAN-
TEC guidelines and our developed NTCP models. The
20- and 25-Gy QUANTEC guidelines are also applied to
the SEF and QoL data in Figures 4 and 5, respectively.The incidences of xerostomia for treatment plans meeting
the QUANTEC guidelines occur precisely when the
spared parotid mean dose is less than the 20- or 25-Gy
cut-off values, giving a NPV of 100% with each dataset. As
seen, the rate of xerostomia for plans meeting our devel-
oped NTCP models are low, for 43.6 Gy cut-off point,
resulting in NPV's of 92% for the SEF data and 95% for
the QoL data, and for 44.1 Gy cut-off point, resulting in
NPV's of 88.9% for the SEF data and 95.5% for the QoL
data, respectively.
Pearson’s chi-squared test demonstrated that the SEF
and QoL data gave similar results (p = 0.241). Based on
Nagelkerke’s R2, the overall NTCP model performance
was similar between the patient-rated xerostomia-related
QoL and the measured SEF values (Table 4). Further-
more, the discrimination based on the AUC was almost
equal between the two datasets, and the Hosmer–Lemeshow
test showed no significant disagreement between the
results determined from each.
Discussion
Parotid gland excretion recovery at 1 year and mean
parotid gland dose were strongly correlated, based on
Lee et al. BMC Cancer 2012, 12:567 Page 7 of 9
http://www.biomedcentral.com/1471-2407/12/567Spearman’s correlation, and mean parotid gland dose
was the only significant predictive factor for xerostomia.
This finding differs from the report by Beetz et al.
[30,31], which proposed that multiple factors are likely
to have separate impacts on xerostomia, although there
may be no racial differences in the parotid gland response
to irradiation.
Whole-mouth salivary function has been shown to be
related to QoL determined by questionnaires [9]. With
LKB NTCP modeling in the present study, the TD50 for
xerostomia 1-year after RT was 43.6 Gy in the SEF ana-
lysis and 44.1 Gy in the QoL analysis. Although these
values are higher than that reported by Moiseenko et al.
(32.4 Gy) [28], they are similar to the TD50 reported by
Dijkema et al. (39.9 Gy), who analyzed the combined
and updated results from two institutions [32]. Deasy
et al. suggested that the wide range of reported TD50
values (28.4 to 52 Gy) may result from differences in
dose distribution, salivary measurement methods, segmen-
tation, intragland sensitivity, and/or patient geographical
location [29].
Xerostomia-specific questionnaires are reliable and
valid for measuring patient-reported xerostomia [10]. In
the present study, QoL data were shown to be as valid
as SEF values for NTCP parameter modeling. Based on
Pearson’s chi-squared test, SEF and QoL data gave simi-
lar results. Furthermore, both the Nagelkerke’s R2, which
describes overall performance, and the AUC demon-
strated that both datasets produced similar results, and
the Hosmer–Lemeshow test showed no significant dis-
agreement between the results determined from the SEF
and QoL data. No significant difference was noted re-
garding dose distributions to the parotid glands.
For the IMRT planning goal, the mean dose to each
parotid gland should be as low as possible while provi-
ding the desired clinical target volume coverage [33].
In our analysis, the incidence of grade 3+ xerostomia
at 1 year was only ~1% or ~2% for the QUANTEC-
recommended cut-off points of 20 Gy or 25 Gy, respec-
tively. Hence, the severe xerostomia would usually be
avoided when at least one parotid gland is spared to a
mean dose ≤20 Gy or when both glands have been
spared to a mean dose ≤25 Gy [29]. A lower parotid
mean dose also results in better QoL for patients [34].
Potential limitations of the present study include the
low number of patients with xerostomia toxicity. Al-
though the SEF values before RT were normally distribu-
ted, confirmation in a larger sample is needed to validate
the NTCP model. Grade selection for the endpoint is
another potential limitation in the present study. Choo-
sing a lower grade of xerostomia may provide more
valuable dose constraints for preventing complications,
as even grade 2 xerostomia significantly diminishes QoL
for patients [34]. We used a previously definition formoderate to severe xerostomia based on the QLQ-HN35
questionnaire [2,30,31]. However, to our knowledge, no
direct evidence exists to clarify this definition or to de-
termine whether it is similar to the grade 3+ xerostomia
definition by the subscales of LENT-SOMA criteria.
Here, we showed the similar NTCP mapping results bet-
ween moderate-to-severe xerostomia and LENT-SOMA
subscales grade 3+ xerostomia. The practical implica-
tions of our results are validation of the use of a QoL
form (EORTC QLQ-H&N35) as a surrogate for whole
mouth salivary function, and also an important vali-
dation of previously proposed QAUNTEC treatment
planning constraints to avoid xerostomia. Therefore, fol-
low the QUANTEC guidelines have benefits to result in
generic QoL improvement. Preserving more gland func-
tion should be pursued as a planning goal when consistent
with adequate target dose coverage. Further researches
will investigate as to whether new radiation techniques or
different study cohorts (combining multiple institutional
or cooperative group data sets) could be further validated
this finding.Conclusions
Our study shows the agreement between the NTCP par-
ameter modeling based on SEF and QoL data and the
QUANTEC guidelines, thus validating the QUANTEC
cut-off values of 20 and 25 Gy. Based on these results,
we believe that the QUANTEC 25/20-Gy spared-gland
mean-dose guidelines are clinically useful for avoiding
xerostomia in the HN cohort.
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